Human Milk Oligosaccharides Market Size

Global Human Milk Oligosaccharides Market Overview

Human milk oligosaccharides market size is expected to reach USD 332.4 Million in the year 2030 and expected to grow at a CAGR of 14.4% during the assessment period. In breast milk, oligosaccharides small sugar molecules called human milk oligosaccharides (HMOs) may be discovered in significant amounts. These nutrients are the 3rd most prevalent component of mother's milk, after lipids and carbs, respectively. As a consequence of the rising use of human milk oligosaccharides in food supplements and the increasing supply of infant formula, the worldwide market for human milk oligosaccharides is developing. The expensive cost of manufacturing, on the other hand, is impeding the expansion of the worldwide human milk oligosaccharides market development.

Growing health awareness has resulted in significant changes in behavior and nutrition over the last several years, increasing the supply of food supplements like nutritional supplements and probiotics throughout the world. Growing evidence supports the use of HMOs in grownup nutrition products such as functional meals and supplementation because of their advantages such as enhancing gut flora and strengthening the defensive system. Aside from encouraging the development of healthy microbes in functional food items and drinks, HMOs have been shown to reduce the presence of dangerous germs like salmonella and campylobacter in drinks and snacks. During the projected period, it is anticipated that these factors would contribute to the market's expansion.

This report contains all the information on the global human milk oligosaccharides market analysis and its strengths. The report also contains the culmination of dynamics, segmentation, key players, regional analysis, and other important factors. And a detailed analysis of the global human milk oligosaccharides market forecast for 2030 is also included in the report.

Covid 19 Analysis

COVID-19 outbreak has a substantial influence here on the Human Milk Oligosaccharides market, according to industry analysts. When the lockdown was implemented, there was a rise in desire for HMOs as a result of panic purchasing for at-home usage during the early period of the epidemic. As a consequence, sales of HMOs increased significantly during the outbreak, owing to the idea that it works like an immunization booster.

Market Dynamic

• Drivers

Market growth will be driven by expanded applications in baby formula, trailed by expanded applications in nutritional supplements, during the projected timeframe. The many health advantages provided by HMOs are also a driving force in the industry. The consolidated prebiotic, antibacterial, and antiadhesive impacts of HMOs make a contribution to trying to shape the newborn gut microbiome early childhood, minimizing the chances of severe illnesses and also the danger of non-conditions such as respiratory problems and allergy symptoms.

• Opportunities

Many enzymes and substances utilized in the production of human milk oligosaccharides are extremely costly and are only available in restricted quantities. This aspect is anticipated to have a negative impact on the human milk oligosaccharides market's growth. Human milk products (HMOs) are most often used in the baby formula industry, trailed by functional foods and drinks. Another reason boosting the demand for human milk oligosaccharides is the need for high-nutrition foods for both adults and children, which is a growing trend.

• Restraints

The absence of technologies for large-scale manufacturing, the massive price of research and development, and the rigorous federal regulations are all expected to limit the expansion of the HMO industry. Baby formula is the most common application sector for the goods, which helps to improve health and avoid illness in newborns by providing them with nutrients. Furthermore, they play an important function in the evolution of the individual brain as well as the increase of recollection in individuals.

• Challenges

It is possible that the high prices connected with the goods would hinder market expansion throughout the projection period.

Cumulative Growth Analysis

Human milk oligosaccharides seem to be the most important elements of human milk, and they may be found in a variety of formulations and quantities. HMOs are considered new foods or substances the essential for appropriate, and their safety must be evaluated. As in the United States, HMOs designed used in foods apart from nutritional supplements have been authorized under the GRAS (Generally Recognized as Safe) Act. CARE4UTM by DuPont has been authorized as GRAS in the United States for use in baby formula and child meals. With the rising desire for HMOs, 2 HMOs went through a new food quality assessment process in Europe in 2021, both of which had a good assessment result and were approved by European Commission in the year 2022.

Value Chain Analysis

According to the reports, the worldwide human milk oligosaccharides market is bifurcated based on the kind of oligosaccharides used, the application of oligosaccharides, as well as the area in which they are used. In terms of kind, the worldwide market for human milk oligosaccharides has been divided into two categories: neutral and acidic. By the end of the year 2030, it is expected that the neutral category would generate USD 563.13 million. The worldwide human milk oligosaccharides market is categorized into two segments based on application: the food industry and laboratory research.

Segmentation Overview

The market is segmented based on the kind of oligosaccharides used, the application of oligosaccharides, and regions. The global human milk oligosaccharides market trend is expected to witness decent growth during the forecast period.

By Application

Based on the application, the market is segmented into the food industry and laboratory research.

By end-users

Based on the propulsion types, the market is segmented into neutral and acidic.

Regional Analysis

According to the reports, Using a regional segmentation approach, the worldwide human milk oligosaccharides market can be segmented into four regions: North America, Europe, China, and Japan. Due to the obvious excessive intake of baby food in the area, North America held the highest proportion of the worldwide human milk oligosaccharides market in the year 2021. For the first time ever in 2021, the Market in Europe for human milk oligosaccharides captured the 2nd largest revenue share of the international economy.

According to a UNICEF study issued in the year 2021, the United Kingdom is among the cheapest levels of breastfed in the globe, with only 34 percent of newborns getting breast milk by the time they hit the age of 6 months. As a result, the low prices of breastfeeding and the increasing number of EU certifications for newly released HMO-based treatments are the most important variables impacting the expansion of the European marketplace. Because of the fall in the newborn count, Japan had the lowest proportion of the worldwide human milk oligosaccharides marketin the year 2021. The Japanese market represented 3.26 percent of the global market in the year 2021.

Competitive Landscape

Developments, innovative products, agreements, and acquisitions were among the primary tactics used by the companies functioning in the worldwide human milk oligosaccharides supplement market.

Major Key Players

•         Abbott (US)


•         BASF SE (Germany)


•         Dextra Laboratories Limited (UK)


•         DuPont Nutrition & Health (Denmark)


•         Elicityl S.A. (France)


•         Glycom (Denmark)


•         Glycosyn LLC (US)


•         Inbiose NV (Belgium)


•         Jennewein Biotechnologie GmbH (Germany)


•         Medolac Laboratories (US)


•         Nestlé Health Science (Switzerland)


•         ZuChem (US)

Report Overview

•         Market overview 


•         Covid 19 Analysis


•         Market Dynamic


•         Drivers


•         Opportunities


•         Restraints 


•         Challenges


•         Cumulative Growth Analysis


•         Value Chain Analysis


•         Segmentation Overview 


•         By Application 


•         By End-Users


•         Regional Analysis


•         Competitive landscape

Recent Developments

• Glycosyn LLC and BASF SE inked an agreement in May 2022 to collaborate on the development and marketing of high-molecular-weight oligomers (HMOs) for general usage in nutritional supplements, healthy nutrition, and therapeutic food. The cooperation and exclusive license will allow BASF SE to expand its provision of the most common HMO, 2'-Fucosyllactose (2'-FL), called PREBILACTM, to developing markets as part of a partnership and exclusive license.


• It was revealed in November 2021 that Glycosyn LLC and Ginkgo Bioworks had entered into a USD 14 million deal to optimize and scale the manufacturing of high molecular weight oligomers (HMOs) for a selection of products that encourage healthy gut microbes ecology and provide medical benefits.


• It was started in October 2021 by Inbiose NV that it has expanded its portfolio to include seven HMOs about which efficient production and commercial procedures were becoming accessible for large-scale manufacture and distribution.

Market Segmentation

Human Milk Oligosaccharides Market, by Type 

• Acidic

• Neutral

Human Milk Oligosaccharides Market, by Application

• Food Industry

• Laboratory Research

Human Milk Oligosaccharides Market, by Region

North America

• U.S.


• Canada


• Mexico

Europe

• Germany


• U.K.


• France

Asia Pacific

• China


• India


• Japan

Central & South America

• Brazil

 Middle East & Africa

• UAE